Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma

Oral Oncology

Volumn 50, Issue 12, 2014, Pages 1149-1156

  Caicedo Granados, Emiro ^a   Lin, Rui ^a   Fujisawa, Caitlin ^a   Yueh, Bevan ^a   Sangwan, Veena ^a   Saluja, Ashok ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

HPV; Minnelide; Oropharyngeal cancer; p53 Reactivation; Preclinical animal model

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; PROTEIN E6; PROTEIN P53; TRIPTOLIDE; 14-O-PHOSPHONOOXYMETHYLTRIPTOLIDE; ALKYLATING AGENT; DITERPENE; EPOXIDE; ORGANOPHOSPHATE; PHENANTHRENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CERVICAL CANCER CELL LINE; CONTROLLED STUDY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; VIRUS REACTIVATION; WART VIRUS; ANIMAL; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS TYPE 16; METABOLISM; PAPILLOMAVIRUS INFECTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; DITERPENES; EPOXY COMPOUNDS; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; ORGANOPHOSPHATES; PAPILLOMAVIRUS INFECTIONS; PHENANTHRENES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84913530461     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.09.013     Document Type: Article

References (26)

1. A.K. Chaturvedi, E.A. Engels, and R.M. Pfeiffer Human papillomavirus and rising oropharyngeal cancer incidence in the United States J Clin Oncol 29 2011 4294 4301
2. M.L. Gillison, T. Broutian, and R.K. Pickard Prevalence of oral HPV infection in the United States, 2009-2010 JAMA 307 2012 693 703
3. A.M. Brinker, J. Ma, P.E. Lipsky, and I. Raskin Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae) Phytochemistry 68 2007 732 766
4. T. Tengchaisri, R. Chawengkirttikul, N. Rachaphaew, V. Reutrakul, R. Sangsuwan, and S. Sirisinha Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters Cancer Lett 133 1998 169 175
5. L.A. Shamon, J.M. Pezzuto, and J.M. Graves Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii Cancer Lett 112 1997 113 117
6. P.A. Phillips, V. Dudeja, and J.A. McCarroll Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70 Cancer Res 67 2007 9407 9416
7. Y.-W. Chen, G.-J. Lin, W.-T. Chia, C.-K. Lin, Y.-P. Chuang, and H.-K. Sytwu Triptolide exerts anti-tumor effect on oral cancer and KB cells in vitro and in vivo Oral Oncol 45 2009 562 568
8. M.B. Antonoff, R. Chugh, and D. Borja-Cacho Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo Surgery 146 2009 282 290
9. R. Chugh, V. Sangwan, and S.P. Patil A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer Sci Translational Med 4 2012 156ra139
10. Velagapudi M, Crowell B. A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced GI Tumors. September 5, 2013. < http://clinicaltrials.gov/ct2/show/NCT01927965?term=minnelide&rank=1 > [accessed 12.11.13].
11. N. Munoz, F.X. Bosch, and S. de Sanjose Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 2003 518 527
12. K. Munger, and P.M. Howley Human papillomavirus immortalization and transformation functions Virus Res 89 2002 213 228
13. W.S. el-Deiry, T. Tokino, and V.E. Velculescu WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825
14. R.L. Ferris, I. Martinez, and N. Sirianni Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis Eur J Cancer 41 2005 807 815
15. T. Rampias, C. Sasaki, P. Weinberger, and A. Psyrri E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells J Natl Cancer Inst 101 2009 412 423
16. J.D. Baleja, J.J. Cherry, and Z. Liu Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins Antiviral Res 72 2006 49 59
17. C.S. Divya, and M.R. Pillai Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis Mol Carcinog 45 2006 320 332
18. C.M. D'Abramo, and J. Archambault Small molecule inhibitors of human papillomavirus protein-protein interactions Open Vir J 5 2011 80 95
19. X. Xie, L. Piao, and B.N. Bullock Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma Oncogene 2013
20. G. Bossi, and A. Sacchi Restoration of wild-type p53 function in human cancer: relevance for tumor therapy Head Neck 29 2007 272 284
21. S. Pearson, H. Jia, and K. Kandachi China approves first gene therapy Nat Biotechnol 22 2004 3 4
22. L.T. Vassilev, B.T. Vu, and B. Graves In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
23. N. Issaeva, P. Bozko, and M. Enge Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors Nat Med 10 2004 1321 1328
24. C. Li, and D.E. Johnson Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest Cell Cycle 12 2013 923 934
25. Z. Lai, T. Yang, and Y.B. Kim Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors Proc Natl Acad Sci USA 99 2002 14734 14739
26. Y. Yang, R.L. Ludwig, and J.P. Jensen Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells Cancer Cell 7 2005 547 559